Quince Therapeutics Inc (NASDAQ: QNCX) on Friday, plunged -6.32% from the previous trading day, before settling in for the closing price of $1.90. Within the past 52 weeks, QNCX’s price has moved between $0.51 and $1.95.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
With a float of $32.62 million, this company’s outstanding shares have now reached $42.97 million.
The firm has a total of 32 workers. Let’s measure their productivity. In terms of profitability, gross margin is -977.78%, operating margin of -134919.44%, and the pretax margin is -147591.67%.
Quince Therapeutics Inc (QNCX) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Quince Therapeutics Inc is 25.87%, while institutional ownership is 11.40%. The most recent insider transaction that took place on Aug 30 ’24, was worth 53,900. In this transaction CEO AND CHIEF MEDICAL OFFICER of this company bought 77,000 shares at a rate of $0.70, taking the stock ownership to the 843,941 shares. Before that another transaction happened on Aug 29 ’24, when Company’s CEO AND CHIEF MEDICAL OFFICER bought 77,500 for $0.69, making the entire transaction worth $53,475. This insider now owns 766,941 shares in total.
Quince Therapeutics Inc (QNCX) Recent Fiscal highlights
For the long-term projections, market analysts anticipate that the company’s EPS will surge by 18.30% during the next five years compared to -12.64% drop over the previous five years of trading.
Quince Therapeutics Inc (NASDAQ: QNCX) Trading Performance Indicators
Quince Therapeutics Inc (QNCX) is currently performing well based on its current performance indicators. A quick ratio of 9.53 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.25, a number that is poised to hit -0.18 in the next quarter
Technical Analysis of Quince Therapeutics Inc (QNCX)
Analysing the last 5-days average volume posted by the [Quince Therapeutics Inc, QNCX], we can find that recorded value of 0.48 million was better than the volume posted last year of 0.23 million. As of the previous 9 days, the stock’s Stochastic %D was 65.12%. Additionally, its Average True Range was 0.21.
During the past 100 days, Quince Therapeutics Inc’s (QNCX) raw stochastic average was set at 78.10%, which indicates a significant increase from 67.54% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 148.51% in the past 14 days, which was higher than the 107.01% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.0101, while its 200-day Moving Average is $0.9463. Now, the first resistance to watch is $2.0701. This is followed by the second major resistance level at $2.3601. The third major resistance level sits at $2.5847. If the price goes on to break the first support level at $1.5555, it is likely to go to the next support level at $1.3309. Now, if the price goes above the second support level, the third support stands at $1.0409.
Quince Therapeutics Inc (NASDAQ: QNCX) Key Stats
Market capitalization of the company is 73.37 million based on 44,002K outstanding shares. Right now, sales total 0 K and income totals -31,390 K. The company made 0 K in profit during its latest quarter, and -27,730 K in sales during its previous quarter.
